Ozempic-maker sues rival, accusing it of false advertising
Summary
Novo Nordisk, the maker of Ozempic and Wegovy, has sued Eli Lilly for false advertising. Novo Nordisk says Eli Lilly's ads misleadingly claim their weight-loss drugs are better by comparing different drug doses unfairly.Key Facts
- Novo Nordisk filed a lawsuit in the US against Eli Lilly for false advertising.
- Eli Lilly makes weight-loss drugs called Mounjaro and Zepbound.
- Novo Nordisk claims Eli Lilly compared its highest drug doses to lower doses of Novo’s drugs, ignoring higher doses Novo offers.
- Novo says Eli Lilly’s ads left out important information about the drugs’ effectiveness.
- Novo Nordisk wants Eli Lilly to stop running these ads and to run new ads correcting the information.
- Novo said if Eli Lilly refuses, it will ask a court to block the ads quickly.
- Both companies are competing in the fast-growing US weight-loss drug market, estimated to be worth more than $100 billion by 2030.
- Novo emphasized that accurate and current drug information is important for people making health decisions.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
